Sanfilippo O, Ronchi E, De Marco C, Di Fronzo G, Silvestrini R
Oncologia Sperimentale C, Milano, Italy.
Eur J Cancer. 1991;27(2):155-8. doi: 10.1016/0277-5379(91)90476-t.
Expression of P-glycoprotein was evaluated by C219 monoclonal antibody immunoblots in 34 previously untreated and 14 pretreated breast cancers and in benign breast lesions or histologically normal breast glands. P-glycoprotein was not detectable in the few cases of normal or benign tissue. P-glycoprotein was expressed in the 170 kD areas of 29% (10/34) of untreated and 64% (9/14) of previously treated tumours (P = 0.02). In treated tumours, high intensity expression was observed more frequently than in untreated breast cancer (40% vs. 9%). Moreover, there was a significant association between P-glycoprotein expression and in vitro resistance to doxorubicin and vincristine. Simultaneous resistance was observed in all of the P-glycoprotein positive and in only 56% of the P-glycoprotein negative tissues (P less than 0.01). Some aspects of the typical multidrug resistant phenotype, such as P-glycoprotein expression and simultaneous resistance to doxorubicin and vincristine, could be detected in small subsets of breast cancer patients. No relation between P-glycoprotein expression and the type of previous clinical treatment was observed.
采用C219单克隆抗体免疫印迹法，对34例未经治疗及14例经治疗的乳腺癌、良性乳腺病变或组织学正常的乳腺组织进行P - 糖蛋白表达评估。在少数正常或良性组织病例中未检测到P - 糖蛋白。P - 糖蛋白在29%（10/34）的未经治疗肿瘤及64%（9/14）的经治疗肿瘤的170kD区域表达（P = 0.02）。在经治疗的肿瘤中，高强度表达比未经治疗的乳腺癌更常见（40%对9%）。此外，P - 糖蛋白表达与对阿霉素和长春新碱的体外耐药性之间存在显著关联。在所有P - 糖蛋白阳性组织中均观察到同时耐药，而在P - 糖蛋白阴性组织中仅56%观察到同时耐药（P小于0.01）。在一小部分乳腺癌患者中可检测到典型多药耐药表型的某些方面，如P - 糖蛋白表达以及对阿霉素和长春新碱的同时耐药。未观察到P - 糖蛋白表达与既往临床治疗类型之间的关系。
